Clinical Trial Search

Primary: MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 — -0.93; -1.15; -0.96; -1.02 Unit on a scale — p== 0.017

Primary: The Safety of Brolucizumab 6 mg Delivered in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration — 0; 0 Participants

Primary: Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video — -0.7 units on a scale

Primary: Opioid Consumption — 40.8; 49.1 Milligram Morphine Equivalents (MME)

Primary: Percentage of Participants With Response Rate — 80.0 Percentage of participants

Primary: Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay — 3.03 percentage of participants

Primary: Percentage of Participants With Stable Vision at Week 52 — 94.8; 91.3; 96.0 percentage of participants

Primary: Number of Participants With Surgeon's Assessment of Procedural Difficulty — 9; 49; 8; 66 Participants

Primary: Mean Change From Pre-Dose to 30 Minutes Post-Dose in The Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part…

Primary: 6-Month (183 Days) Cumulative Pregnancy Percentage — 10.0; 10.5 pregnancy percentage

Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score During Week 8 — -3.8; -2.8; -3.2; -1.9 score on a scale — p=<0.001

Primary: Percentage of Participants With Stable Vision at Week 52 — 91.7; 91.2; 95.5 percentage of participants

Primary: Rate of Clinical Decline — 11.116; 9.860 score per year — p=0.183

Primary: Change From Baseline in Serum Phosphorus at Week 8 — 2.090; 2.095; 0.010; -0.200 mmol/L — p=<0.0001

Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…